Sanofi - Aventis: FDA Grants Priority Review To Efanesoctocog Alfa For Rare Bleeding Disorder
PARIS (dpa-AFX) - The U.S. Food and Drug Administration has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A,…
Sanofi - Aventis: FDA Grants Priority Review To Efanesoctocog Alfa For Rare Bleeding Disorder
PARIS (dpa-AFX) - The U.S. Food and Drug Administration has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A,…